lynch biologics, the founder of american biomedical company, visited icap -买球的app排行榜
on april 4, the founder of lynch biologics (an american biomedical company), dr sam lynch, visited icap with a project. the company of dr sam lynch has been listed on nasdaq. dr sam lynch introduced a series of medicine developed by lynch biologics based on rhpdgf (including approved marketing and progress to clinical phase ii), including a series of therapeutic medicine for diabetic foot ulcers, dentistry and orthopaedics. dr sam lynch hopes the project can transform into reality in china through icap.
on april 4, the founder of lynch biologics (an american biomedical company), dr. sam lynch, paid a visit to icap with a project. the company of dr sam lynch has been listed on nasdaq.
dr. sam lynch introduced a series of medicine developed by lynch biologics based on rhpdgf (including approved marketing and progress to clinical phase ii), including a series of therapeutic medicine for diabetic foot ulcers, dentistry and orthopaedics. dr. sam lynch hopes that the project can be transformed into reality in china through icap.
company profile——lynch biologics
lynch biologics is a bio biotech corp dedicated to regenerative medicine that uses particular bioactive proteins to treat patients with skin and bone injuries. it pays great attention to 4 areas, including wound healing of diabetic foot ulcers, postoperative wound complications, dental/craniofacial bone and soft tissue regeneration, and supply protein growth factor for mesenchymal stem cell therapy.
team structure
dr. sam lynch is the company's founder and ceo; sam lynch graduated and now teaches at harvard medical school and harvard school of dental medicine. he has published over 100 papers in scientific journals and issued 150 patents all around the world.
sam lynch was one of the founders of biomimetic therapeutics (nasdaq: bmti). biomimetic is a biological products company specializing in promoting bone injury and disease treatment, with several products approved by fda. sam lynch is the technical inventor of the approved medicine and led the team to obtain the gem 21s listing permission and augment bone graft in the u.s. and international markets successfully.
in 2012, biomimetic was acquired by wright medical group at $380 million u.s. dollars. the company's senior vice president of manufacturing operations and vice president of business operations are both from biomimetic therapeutics.
